{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:39:28Z","timestamp":1785008368674,"version":"3.55.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12664-024-01524-2","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T13:02:26Z","timestamp":1706965346000},"page":"48-63","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Perianal fistulizing Crohn\u2019s disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies"],"prefix":"10.1007","volume":"43","author":[{"given":"Jalpa","family":"Devi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Aswani-Omprakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa M.","family":"Parian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3436-9784","authenticated-orcid":false,"given":"Parakkal","family":"Deepak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"key":"1524_CR1","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nrgastro.2017.104","volume":"14","author":"J Pan\u00e9s","year":"2017","unstructured":"Pan\u00e9s J, Rimola J. Perianal fistulizing Crohn\u2019s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:652\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1524_CR2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1053\/gast.2002.32362","volume":"122","author":"DA Schwartz","year":"2002","unstructured":"Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn\u2019s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875\u201380.","journal-title":"Gastroenterology"},{"key":"1524_CR3","doi-asserted-by":"crossref","unstructured":"Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Perianal disease predicts changes in Crohn\u2019s disease phenotype\u2014results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol. 2008;103:3082\u201393.","DOI":"10.1111\/j.1572-0241.2008.02212.x"},{"key":"1524_CR4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/ibd\/izab287","volume":"28","author":"L Tsai","year":"2022","unstructured":"Tsai L, McCurdy JD, Ma C, Jairath V, Singh S. Epidemiology and natural history of perianal Crohn\u2019s disease: a systematic review and meta-analysis of population-based cohorts. Inflamm Bowel Dis. 2022;28:1477\u201384.","journal-title":"Inflamm Bowel Dis"},{"key":"1524_CR5","unstructured":"Beaugerie L, Carrat F, Nahon S, et al. High risk of anal and rectal cancer in patients with anal and\/or perianal Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2018;16:892\u20139.e2."},{"key":"1524_CR6","doi-asserted-by":"crossref","unstructured":"Ganapathy A, Navale P, Mutch MG, Kim H, Ballard DH, Deepak P. Long-standing symptomatic fistulizing perianal Crohn\u2019s disease: progression beyond inflammation. Gastroenterology. 2024;166:36\u201343.e2.","DOI":"10.1053\/j.gastro.2023.09.007"},{"key":"1524_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5217\/ir.2017.15.1.138","volume":"15","author":"P Singh","year":"2017","unstructured":"Singh P, Ananthakrishnan A, Ahuja V. Pivot to Asia: inflammatory bowel disease burden. Intest Res. 2017;15:138\u201341.","journal-title":"Intest Res"},{"key":"1524_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000465522","volume":"2","author":"S Kedia","year":"2017","unstructured":"Kedia S, Ahuja V. Epidemiology of inflammatory bowel disease in India: the great shift east. Inflamm Intest Dis. 2017;2:102\u201315.","journal-title":"Inflamm Intest Dis"},{"key":"1524_CR9","doi-asserted-by":"crossref","unstructured":"Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn\u2019s and colitis epidemiology study. Gastroenterology. 2013;145:158\u201365.e2.","DOI":"10.1053\/j.gastro.2013.04.007"},{"key":"1524_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s10620-008-0469-6","volume":"54","author":"K Das","year":"2009","unstructured":"Das K, Ghoshal UC, Dhali GK, Benjamin J, Ahuja V, Makharia GK. Crohn\u2019s disease in India: a multicenter study from a country where tuberculosis is endemic. Dig Dis Sci. 2009;54:1099\u2013107.","journal-title":"Dig Dis Sci"},{"key":"1524_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12664-015-0539-6","volume":"34","author":"BS Ramakrishna","year":"2015","unstructured":"Ramakrishna BS, Makharia GK, Ahuja V, et al. Indian Society of Gastroenterology consensus statements on Crohn\u2019s disease in India. Indian J Gastroenterol. 2015;34:3\u201322.","journal-title":"Indian J Gastroenterol"},{"key":"1524_CR12","doi-asserted-by":"publisher","first-page":"8123","DOI":"10.3748\/wjg.v22.i36.8123","volume":"22","author":"G Ray","year":"2016","unstructured":"Ray G. Inflammatory bowel disease in India-Past, present and future. World J Gastroenterol. 2016;22:8123\u201336.","journal-title":"World J Gastroenterol"},{"key":"1524_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s12664-012-0293-y","volume":"32","author":"A Goel","year":"2013","unstructured":"Goel A, Dutta AK, Pulimood AB, Eapen A, Chacko A. Clinical profile and predictors of disease behavior and surgery in Indian patients with Crohn\u2019s disease. Indian J Gastroenterol. 2013;32:184\u20139.","journal-title":"Indian J Gastroenterol"},{"key":"1524_CR14","first-page":"22","volume":"4","author":"JY Kim","year":"2006","unstructured":"Kim JY, Yang S-K, Byeon J-S, et al. The incidence and natural history of perianal fistulas in Korean patients with Crohn\u2019s disease. Intestinal Res. 2006;4:22\u201331.","journal-title":"Intestinal Res"},{"key":"1524_CR15","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/ibd\/izaa029","volume":"26","author":"S Jangi","year":"2020","unstructured":"Jangi S, Ruan A, Korzenik J, de Silva P. South Asian patients with inflammatory bowel disease in the United States demonstrate more fistulizing and perianal crohn phenotype. Inflamm Bowel Dis. 2020;26:1933\u201342.","journal-title":"Inflamm Bowel Dis"},{"key":"1524_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000484347","volume":"2","author":"B Kochar","year":"2018","unstructured":"Kochar B, Barnes EL, Herfarth HH, et al. Asians have more perianal Crohn disease and ocular manifestations compared with white Americans. Inflamm Intest Dis. 2018;2:147\u201353.","journal-title":"Inflamm Intest Dis"},{"key":"1524_CR17","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/ecco-jcc\/jjad008","volume":"17","author":"S Cao","year":"2023","unstructured":"Cao S, Colonna M, Deepak P. Pathogenesis of perianal fistulising Crohn\u2019s disease: current knowledge, gaps in understanding, and future research directions. J Crohns Colitis. 2023;17:1010\u201322.","journal-title":"J Crohns Colitis"},{"key":"1524_CR18","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1016\/j.cgh.2020.12.024","volume":"20","author":"C Brochard","year":"2022","unstructured":"Brochard C, Rabilloud M-L, Hamonic S, et al. Natural history of perianal Crohn\u2019s disease: long-term follow-up of a population-based cohort. Clin Gastroenterol Hepatol. 2022;20:e102\u201310.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1524_CR19","doi-asserted-by":"crossref","unstructured":"Danielou M, Sarter H, Pariente B, et al. Natural history of perianal fistulising lesions in patients with elderly-onset Crohn\u2019s disease: a population-based study. J Crohns Colitis. 2020;14:501\u20137.","DOI":"10.1093\/ecco-jcc\/jjz173"},{"key":"1524_CR20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/ecco-jcc\/jjac032","volume":"16","author":"J Breton","year":"2022","unstructured":"Breton J, Tanes C, Tu V, Albenberg L, Rowley S, Devas N, et al. A microbial signature for paediatric perianal Crohn\u2019s disease. J Crohns Colitis. 2022;16:1281\u201392.","journal-title":"J Crohns Colitis"},{"key":"1524_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jss.2019.04.032","volume":"242","author":"BE Haac","year":"2019","unstructured":"Haac BE, Palmateer NC, Seaton ME, VanYPeren R, Fraser CM, Bafford AC. A distinct gut microbiota exists within Crohn\u2019s disease\u2013related perianal fistulae. J Surg Res. 2019;242:118\u201328.","journal-title":"J Surg Res"},{"key":"1524_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/bjs.1800790107","volume":"79","author":"F Seow-Choen","year":"1992","unstructured":"Seow-Choen F, Hay A, Heard S, Phillips R. Bacteriology of anal fistulae. J Br Surg. 1992;79:27\u20138.","journal-title":"J Br Surg"},{"key":"1524_CR23","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1097\/MEG.0000000000001976","volume":"33","author":"SO Adegbola","year":"2021","unstructured":"Adegbola SO, Sarafian M, Sahnan K, et al. Differences in amino acid and lipid metabolism distinguish Crohn\u2019s from idiopathic\/cryptoglandular perianal fistulas by tissue metabonomic profiling and may offer clues to underlying pathogenesis. Eur J Gastroenterol Hepatol. 2021;33:1469\u201379.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1524_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bjs.1800630102","volume":"63","author":"A Parks","year":"1976","unstructured":"Parks A, Gordon PH, Hardcastle J. A classification of fistula-in-ano. Br J Surg. 1976;63:1\u201312.","journal-title":"Br J Surg"},{"key":"1524_CR25","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.gastro.2003.08.025","volume":"125","author":"WJ Sandborn","year":"2003","unstructured":"Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn\u2019s disease. Gastroenterology. 2003;125:1508\u201330.","journal-title":"Gastroenterology"},{"key":"1524_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S2468-1253(22)00007-3","volume":"7","author":"J Geldof","year":"2022","unstructured":"Geldof J, Iqbal N, LeBlanc J-F, et al. Classifying perianal fistulising Crohn\u2019s disease: an expert consensus to guide decision-making in daily practice and clinical trials. Lancet Gastroenterol Hepatol. 2022;7:576\u201384.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1524_CR27","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1053\/gast.2001.28676","volume":"121","author":"DA Schwartz","year":"2001","unstructured":"Schwartz DA, Wiersema MJ, Dudiak KM, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn\u2019s perianal fistulas. Gastroenterology. 2001;121:1064\u201372.","journal-title":"Gastroenterology"},{"key":"1524_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/MOG.0000000000000751","volume":"37","author":"S Abushamma","year":"2021","unstructured":"Abushamma S, Ballard DH, Smith RK, Deepak P. Multidisciplinary management of perianal Crohn\u2019s disease. Curr Opin Gastroenterol. 2021;37:295\u2013305.","journal-title":"Curr Opin Gastroenterol"},{"key":"1524_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1055\/s-0043-103954","volume":"38","author":"G Maconi","year":"2017","unstructured":"Maconi G, Greco MT, Asthana AK. Transperineal ultrasound for perianal fistulas and abscesses - a systematic review and meta-analysis. Ultraschall Med. 2017;38:265\u201372.","journal-title":"Ultraschall Med"},{"key":"1524_CR30","doi-asserted-by":"crossref","unstructured":"Cerit MN, \u00d6ner AY, Y\u0131ld\u0131z A, Cindil E, \u015eendur HN, Levento\u011flu S. Perianal fistula mapping at 3 T: volumetric versus conventional MRI sequences. Clin Radiol. 2020;75:563.e1\u2013.e9.","DOI":"10.1016\/j.crad.2020.03.034"},{"key":"1524_CR31","doi-asserted-by":"publisher","first-page":"S268","DOI":"10.1016\/j.jacr.2021.08.009","volume":"18","author":"AD Levy","year":"2021","unstructured":"Levy AD, Liu PS, Kim DH, et al. ACR Appropriateness Criteria\u00ae Anorectal Disease. J Am Coll Radiol. 2021;18:S268-s82.","journal-title":"J Am Coll Radiol"},{"key":"1524_CR32","doi-asserted-by":"crossref","unstructured":"Irvine EJ. Usual therapy improves perianal Crohn\u2019s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol. 1995;20:27\u201332.","DOI":"10.1097\/00004836-199501000-00008"},{"key":"1524_CR33","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1136\/gutjnl-2019-320553","volume":"70","author":"SO Adegbola","year":"2021","unstructured":"Adegbola SO, Dibley L, Sahnan K, et al. Development and initial psychometric validation of a patient-reported outcome measure for Crohn\u2019s perianal fistula: the Crohn\u2019s Anal Fistula Quality of Life (CAF-QoL) scale. Gut. 2021;70:1649\u201356.","journal-title":"Gut"},{"key":"1524_CR34","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/apt.14190","volume":"46","author":"MA Samaan","year":"2017","unstructured":"Samaan MA, Puylaert CA, Levesque BG, et al. The development of a magnetic resonance imaging index for fistulising Crohn\u2019s disease. Aliment Pharmacol Ther. 2017;46:516\u201328.","journal-title":"Aliment Pharmacol Ther"},{"key":"1524_CR35","doi-asserted-by":"crossref","unstructured":"Hindryckx P, Jairath V, Zou G, et al. Development and validation of a magnetic resonance index for assessing fistulas in patients with Crohn\u2019s disease. Gastroenterology. 2019;157:1233\u201344.e5.","DOI":"10.1053\/j.gastro.2019.07.027"},{"key":"1524_CR36","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/ibd\/izab147","volume":"28","author":"S Choshen","year":"2022","unstructured":"Choshen S, Turner D, Pratt L-T, et al. Development and validation of a pediatric MRI-based perianal Crohn disease (PEMPAC) index\u2014a report from the ImageKids Study. Inflamm Bowel Dis. 2022;28:700\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1524_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ibd.20608","volume":"15","author":"KT Thia","year":"2009","unstructured":"Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn\u2019s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15:17\u201324.","journal-title":"Inflamm Bowel Dis"},{"key":"1524_CR38","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1046\/j.1365-2036.2003.01793.x","volume":"18","author":"C Dejaco","year":"2003","unstructured":"Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn\u2019s disease. Aliment Pharmacol Ther. 2003;18:1113\u201320.","journal-title":"Aliment Pharmacol Ther"},{"key":"1524_CR39","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/j.1365-2036.2004.02247.x","volume":"20","author":"R West","year":"2004","unstructured":"West R, Van der Woude C, Hansen B, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn\u2019s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329\u201336.","journal-title":"Aliment Pharmacol Ther"},{"key":"1524_CR40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/gutjnl-2013-304488","volume":"63","author":"P Dewint","year":"2014","unstructured":"Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn\u2019s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292\u20139.","journal-title":"Gut"},{"key":"1524_CR41","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0016-5085(82)80332-6","volume":"83","author":"LJ Brandt","year":"1982","unstructured":"Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn\u2019s disease: a follow-up study. Gastroenterology. 1982;83:383\u20137.","journal-title":"Gastroenterology"},{"key":"1524_CR42","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"JD Feuerstein","year":"2021","unstructured":"Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease. Gastroenterology. 2021;160:2496\u2013508.","journal-title":"Gastroenterology"},{"key":"1524_CR43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/01.MIB.0000172811.57242.18","volume":"11","author":"DA Schwartz","year":"2005","unstructured":"Schwartz DA, White CM, Wise PE, Herline AJ. Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn\u2019s perianal fistulas. Inflamm Bowel Dis. 2005;11:727\u201332.","journal-title":"Inflamm Bowel Dis"},{"key":"1524_CR44","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.cgh.2018.01.030","volume":"16","author":"MJ Lee","year":"2018","unstructured":"Lee MJ, Parker CE, Taylor SR, et al. Efficacy of medical therapies for fistulizing Crohn\u2019s disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1879\u201392.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1524_CR45","doi-asserted-by":"publisher","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","volume":"123","author":"DC Pearson","year":"1995","unstructured":"Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med. 1995;123:132\u201342.","journal-title":"Ann Intern Med"},{"key":"1524_CR46","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/00004836-200004000-00018","volume":"30","author":"WC Jeshion","year":"2000","unstructured":"Jeshion WC, Larsen KL, Jawad AF, et al. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn\u2019s disease in children. J Clin Gastroenterol. 2000;30:294\u20138.","journal-title":"J Clin Gastroenterol"},{"key":"1524_CR47","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s12664-020-01054-7","volume":"39","author":"SK Vuyyuru","year":"2020","unstructured":"Vuyyuru SK, Sahu P, Kedia S, et al. Long-term outcomes in perianal fistulizing Crohn\u2019s disease in a resource-limited setting: a cohort analysis. Indian J Gastroenterol. 2020;39:435\u201344.","journal-title":"Indian J Gastroenterol"},{"key":"1524_CR48","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1046\/j.1365-2036.2003.01790.x","volume":"18","author":"U Mahadevan","year":"2003","unstructured":"Mahadevan U, Marion J, Present D. Fistula response to methotrexate in Crohn\u2019s disease: a case series. Aliment Pharmacol Ther. 2003;18:1003\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"1524_CR49","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/00054725-199811000-00014","volume":"4","author":"A Kornbluth","year":"1998","unstructured":"Kornbluth A. Infliximab approved for use in Crohn\u2019s disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis. 1998;4:328\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1524_CR50","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med. 1999;340:1398\u2013405.","journal-title":"N Engl J Med"},{"key":"1524_CR51","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350:876\u201385.","journal-title":"N Engl J Med"},{"key":"1524_CR52","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/ecco-jcc\/jjaa004","volume":"14","author":"KA Wasmann","year":"2020","unstructured":"Wasmann KA, de Groof EJ, Stellingwerf ME, et al. Treatment of perianal fistulas in Crohn\u2019s disease, seton versus anti-TNF versus surgical closure following anti-TNF [PISA]: a randomised controlled trial. J Crohn\u2019s Colitis. 2020;14:1049\u201356.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1524_CR53","doi-asserted-by":"crossref","unstructured":"Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn\u2019s disease. Am J Gastroenterol. 2003;98:332\u20139.","DOI":"10.1111\/j.1572-0241.2003.07241.x"},{"key":"1524_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/00054725-200403000-00005","volume":"10","author":"S Ardizzone","year":"2004","unstructured":"Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Porro GB. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis. 2004;10:91\u20136.","journal-title":"Inflamm Bowel Dis"},{"key":"1524_CR55","doi-asserted-by":"crossref","unstructured":"Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn\u2019s disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:975\u201381.e4.","DOI":"10.1016\/j.cgh.2012.12.042"},{"key":"1524_CR56","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132:52\u201365.","journal-title":"Gastroenterology"},{"key":"1524_CR57","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/gut.2008.159251","volume":"58","author":"J-F Colombel","year":"2009","unstructured":"Colombel J-F, Schwartz DA, Sandborn WJ, Kamm MA, D\u2019Haens G, Rutgeerts P, et al. Adalimumab for the treatment of fistulas in patients with Crohn\u2019s disease. Gut. 2009;58:940\u20138.","journal-title":"Gut"},{"key":"1524_CR58","doi-asserted-by":"crossref","unstructured":"Fu Y-m, Chen M, Liao A-j. A meta-analysis of adalimumab for fistula in Crohn\u2019s disease. Gastroenterol Res Pract. 2017;2017:1745692.","DOI":"10.1155\/2017\/1745692"},{"key":"1524_CR59","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1365-2036.2010.04466.x","volume":"32","author":"S Lichtiger","year":"2010","unstructured":"Lichtiger S, Binion D, Wolf D, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn\u2019s disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32:1228\u201339.","journal-title":"Aliment Pharmacol Ther"},{"key":"1524_CR60","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.14309\/ajg.0000000000001111","volume":"116","author":"K Papamichael","year":"2021","unstructured":"Papamichael K, Casteele NV, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. Higher post-induction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn\u2019s disease: an ACCENT-II post-hoc analysis. Am J Gastroenterol. 2021;116:1007.","journal-title":"Am J Gastroenterol"},{"key":"1524_CR61","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/apt.13970","volume":"45","author":"AJ Yarur","year":"2017","unstructured":"Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn\u2019s disease. Aliment Pharmacol Ther. 2017;45:933\u201340.","journal-title":"Aliment Pharmacol Ther."},{"key":"1524_CR62","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.cgh.2021.07.053","volume":"20","author":"M De Gregorio","year":"2022","unstructured":"De Gregorio M, Lee T, Krishnaprasad K, et al. Higher anti-tumor necrosis factor-\u03b1 levels correlate with improved radiologic outcomes in Crohn\u2019s perianal fistulas. Clin Gastroenterol Hepatol. 2022;20:1306\u201314.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1524_CR63","doi-asserted-by":"crossref","unstructured":"Zulqarnain M, Deepak P, Yarur AJ. Therapeutic drug monitoring in perianal fistulizing Crohn\u2019s disease. J Clin Med. 2022;11:1813.","DOI":"10.3390\/jcm11071813"},{"key":"1524_CR64","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/S0016-5085(17)30930-7","volume":"152","author":"BE Sands","year":"2017","unstructured":"Sands BE, Gasink C, Jacobstein D, et al. Fistula healing in pivotal studies of ustekinumab in Crohn\u2019s disease. Gastroenterology. 2017;152:S185.","journal-title":"Gastroenterology"},{"key":"1524_CR65","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/00365521.2020.1854848","volume":"56","author":"M Attauabi","year":"2021","unstructured":"Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn\u2019s disease: a systematic review and meta-analysis of the current literature. Scand J Gastroenterol. 2021;56:53\u20138.","journal-title":"Scand J Gastroenterol"},{"key":"1524_CR66","doi-asserted-by":"crossref","unstructured":"Chapuis-Biron C, Kirchgesner J, Pariente B, et al. Ustekinumab for perianal Crohn\u2019s disease: the BioLAP multicenter study from the GETAID. Am J Gastroenterol. 2020;115:1812\u201320.","DOI":"10.14309\/ajg.0000000000000810"},{"key":"1524_CR67","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/ecco-jcc\/jjy019","volume":"12","author":"BG Feagan","year":"2018","unstructured":"Feagan BG, Schwartz D, Danese S, et al. Efficacy of vedolizumab in fistulising Crohn\u2019s disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis. 2018;12:621\u20136.","journal-title":"J Crohns Colitis"},{"key":"1524_CR68","doi-asserted-by":"crossref","unstructured":"Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn\u2019s disease: ENTERPRISE study. Clin Gastroenterol Hepatol. 2022;20:1059\u201367.e9.","DOI":"10.1016\/j.cgh.2021.09.028"},{"key":"1524_CR69","doi-asserted-by":"publisher","first-page":"240","DOI":"10.5217\/ir.2021.00091","volume":"20","author":"F Ayoub","year":"2022","unstructured":"Ayoub F, Odenwald M, Micic D, et al. Vedolizumab for perianal fistulizing Crohn\u2019s disease: systematic review and meta-analysis. Intest Res. 2022;20:240\u201350.","journal-title":"Intest Res"},{"key":"1524_CR70","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/apt.15719","volume":"51","author":"E Yang","year":"2020","unstructured":"Yang E, Panaccione N, Whitmire N, et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease. Aliment Pharmacol Ther. 2020;51:1031\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"1524_CR71","doi-asserted-by":"crossref","unstructured":"Huff-Hardy K, Bedair M, Vazquez R, Burstein E. Efficacy of combination vedolizumab and ustekinumab for refractory Crohn\u2019s disease. Inflamm Bowel Dis. 2017;23:E49\u2013E.","DOI":"10.1097\/MIB.0000000000001232"},{"key":"1524_CR72","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/ueg2.12170","volume":"9","author":"L Goessens","year":"2021","unstructured":"Goessens L, Colombel JF, Outtier A, et al. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: a European retrospective observational study. UEG J. 2021;9:1136\u201347.","journal-title":"UEG J"},{"key":"1524_CR73","doi-asserted-by":"crossref","unstructured":"Chahal J, Sriranganathan D, Poo S, et al. P642 Network meta-analysis: efficacy and safety of treatments for fistulising Crohn\u2019s disease. J Crohns Colitis. 2023;17 Supplement_1:i773\u2013i4.","DOI":"10.1093\/ecco-jcc\/jjac190.0772"},{"key":"1524_CR74","doi-asserted-by":"crossref","unstructured":"Colombel J, Irving P, Rieder F, et al. P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn\u2019s disease. J Crohns Colitis. 2023;17 Supplement_1:i620\u2013i3.","DOI":"10.1093\/ecco-jcc\/jjac190.0621"},{"key":"1524_CR75","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266\u201375.","journal-title":"Lancet"},{"key":"1524_CR76","doi-asserted-by":"crossref","unstructured":"D'Haens GR, Lee S, Taylor SA, et al. Filgotinib for the treatment of small bowel Crohn\u2019s disease: the DIVERGENCE 1 Trial. Gastroenterology. 2023;165:289\u201392.e3.","DOI":"10.1053\/j.gastro.2023.03.234"},{"key":"1524_CR77","unstructured":"DIVERSITY GatrfP, trial of filgotinib in Crohn\u2019s disease A. 2023. https:\/\/www.glpg.com\/press-release\/3766\/galapagos-announces-toplineresults-from-phase-3-diversity-trial-of-filgotinib-in-crohn-sdisease. Accessed 10 November 2023."},{"key":"1524_CR78","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1097\/MEG.0000000000002164","volume":"33","author":"AK Singh","year":"2021","unstructured":"Singh AK, Jha DK, Jena A, Kumar-M P, Sebastian S, Sharma V. Hyperbaric oxygen therapy in inflammatory bowel disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2021;33:e564\u201373.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1524_CR79","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/apt.16228","volume":"53","author":"CA Lansdorp","year":"2021","unstructured":"Lansdorp CA, Gecse KB, Buskens CJ, et al. Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn\u2019s disease. Aliment Pharmacol Ther. 2021;53:587\u201397.","journal-title":"Aliment Pharmacol Ther"},{"key":"1524_CR80","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11605-006-0068-9","volume":"11","author":"A Fichera","year":"2007","unstructured":"Fichera A, Michelassi F. Surgical treatment of Crohn\u2019s disease. J Gastrointest Surg. 2007;11:791\u2013803.","journal-title":"J Gastrointest Surg"},{"key":"1524_CR81","first-page":"3","volume":"57","author":"S Tanaka","year":"2010","unstructured":"Tanaka S, Matsuo K, Sasaki T, et al. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn\u2019s disease: when and how were the seton drains removed? Hepatogastroenterology. 2010;57:3\u20137.","journal-title":"Hepatogastroenterology"},{"key":"1524_CR82","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2018;113:481\u2013517.","journal-title":"Am J Gastroenterol"},{"key":"1524_CR83","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S2468-1253(22)00088-7","volume":"7","author":"EM Meima-van Praag","year":"2022","unstructured":"Meima-van Praag EM, van Rijn KL, Wasmann KA, et al. Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn\u2019s disease (PISA-II): a patient preference randomised trial. Lancet Gastroenterol Hepatol. 2022;7:617\u201326.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1524_CR84","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/BF02058706","volume":"39","author":"YP Sangwan","year":"1996","unstructured":"Sangwan YP, Schoetz DJ, Murray JJ, Roberts PL, Coller JA. Perianal Crohn\u2019s disease: results of local surgical treatment. Dis Colon Rectum. 1996;39:529\u201335.","journal-title":"Dis Colon Rectum"},{"key":"1524_CR85","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1177\/0003134820956331","volume":"87","author":"JL Williams","year":"2021","unstructured":"Williams JL, Shaffer VO. Modern management of perianal Crohn\u2019s disease: a review. Am Surg. 2021;87:1361\u20137.","journal-title":"Am Surg"},{"key":"1524_CR86","first-page":"339","volume":"67","author":"G Murtaza","year":"2017","unstructured":"Murtaza G, Shaikh FA, Chawla T, Haider BA, Shahzad N, Ansari S. Fistulotomy versus fistulectomy for simple fistula in ano: a retrospective cohort study. J Pak Med Assoc. 2017;67:339.","journal-title":"J Pak Med Assoc"},{"key":"1524_CR87","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1136\/gutjnl-2013-306709","volume":"63","author":"KB Gecse","year":"2014","unstructured":"Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn\u2019s disease. Gut. 2014;63:1381\u201392.","journal-title":"Gut"},{"key":"1524_CR88","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/bjs5.50129","volume":"3","author":"M Stellingwerf","year":"2019","unstructured":"Stellingwerf M, Van Praag E, Tozer P, Bemelman W, Buskens C. Systematic review and meta-analysis of endorectal advancement flap and ligation of the intersphincteric fistula tract for cryptoglandular and Crohn\u2019s high perianal fistulas. BJS Open. 2019;3:231\u201341.","journal-title":"BJS Open"},{"key":"1524_CR89","first-page":"581","volume":"90","author":"A Rojanasakul","year":"2007","unstructured":"Rojanasakul A, Pattanaarun J, Sahakitrungruang C, Tantiphlachiva K. Total anal sphincter saving technique for fistula-in-ano; the ligation of intersphincteric fistula tract. J Med Assoc Thail. 2007;90:581.","journal-title":"J Med Assoc Thail"},{"key":"1524_CR90","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10151-022-02582-4","volume":"26","author":"T Wood","year":"2022","unstructured":"Wood T, Truong A, Mujukian A, Zaghiyan K, Fleshner P. Increasing experience with the LIFT procedure in Crohn\u2019s disease patients with complex anal fistula. Tech Coloproctol. 2022;26:205\u201312.","journal-title":"Tech Coloproctol"},{"key":"1524_CR91","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1097\/SLA.0000000000000479","volume":"260","author":"DS Gingold","year":"2014","unstructured":"Gingold DS, Murrell ZA, Fleshner PR. A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with Crohn\u2019s disease. Ann Surg. 2014;260:1057\u201361.","journal-title":"Ann Surg"},{"key":"1524_CR92","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10151-011-0769-2","volume":"15","author":"P Meinero","year":"2011","unstructured":"Meinero P, Mori L. Video-assisted anal fistula treatment (VAAFT): a novel sphincter-saving procedure for treating complex anal fistulas. Tech Coloproctol. 2011;15:417\u201322.","journal-title":"Tech Coloproctol"},{"key":"1524_CR93","first-page":"1067","volume":"12","author":"SO Adegbola","year":"2018","unstructured":"Adegbola SO, Sahnan K, Tozer PJ, et al. Symptom amelioration in Crohn\u2019s perianal fistulas using video-assisted anal fistula treatment (VAAFT). J Crohns Colitis. 2018;12:1067\u201372.","journal-title":"J Crohns Colitis"},{"key":"1524_CR94","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s002680010250","volume":"24","author":"T Yamamoto","year":"2000","unstructured":"Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn\u2019s disease. World J Surg. 2000;24:1258\u201363.","journal-title":"World J Surg"},{"key":"1524_CR95","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/apt.13356","volume":"42","author":"S Singh","year":"2015","unstructured":"Singh S, Ding NS, Mathis KL, et al. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn\u2019s disease. Aliment Pharmacol Ther. 2015;42:783\u201392.","journal-title":"Aliment Pharmacol Ther"},{"key":"1524_CR96","doi-asserted-by":"crossref","unstructured":"Jew M, Meserve J, Eisenstein S, Jairath V, McCurdy J, Singh S. Temporary faecal diversion for refractory perianal and\/or distal colonic Crohn\u2019s disease in the biologic era: an updated systematic review with meta-analysis. J Crohns Colitis. 2023:jjad159.","DOI":"10.1093\/ecco-jcc\/jjad159"},{"key":"1524_CR97","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1097\/DCR.0000000000001748","volume":"63","author":"AL Lightner","year":"2020","unstructured":"Lightner AL. Perianal Crohn\u2019s disease. Dis Colon Rectum. 2020;63:1023\u20136.","journal-title":"Dis Colon Rectum"},{"key":"1524_CR98","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/bjs.4613","volume":"91","author":"B Singh","year":"2004","unstructured":"Singh B, McC Mortensen N, Jewell D, George B. Perianal Crohn\u2019s disease. J Br Surg. 2004;91:801\u201314.","journal-title":"J Br Surg"},{"key":"1524_CR99","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ibd.21311","volume":"17","author":"Y Maeda","year":"2011","unstructured":"Maeda Y, Heyckendorff-Diebold T, Tei TM, Lundby L, Buntzen S. Gracilis muscle transposition for complex fistula and persistent nonhealing sinus in perianal Crohn\u2019s disease. Inflamm Bowel Dis. 2011;17:583\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1524_CR100","doi-asserted-by":"crossref","unstructured":"Buscail E, Le Cosquer G, Gross F, et al. Adipose-derived stem cells in the treatment of perianal fistulas in Crohn\u2019s disease: rationale, clinical results and perspectives. Int J Mol Sci. 2021;22:9967.","DOI":"10.3390\/ijms22189967"},{"key":"1524_CR101","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1136\/gutjnl-2017-314918","volume":"67","author":"PG Kotze","year":"2018","unstructured":"Kotze PG, Shen B, Lightner A, et al. Modern management of perianal fistulas in Crohn\u2019s disease: future directions. Gut. 2018;67:1181\u201394.","journal-title":"Gut"},{"issue":"5","key":"1524_CR102","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/ibd\/izz215","volume":"26","author":"AL Lightner","year":"2019","unstructured":"Lightner AL, Dozois EJ, Dietz AB, et al. Matrix-delivered autologous mesenchymal stem cell therapy for refractory rectovaginal Crohns fistulas. Inflamm Bowel Dis. 2019;26:670\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"1524_CR103","doi-asserted-by":"crossref","unstructured":"Lightner AL, Reese JS, Ream J, et al. A phase IB\/IIA study of ex vivo expanded allogeneic bone marrow derived mesenchymal stem cells for the treatment of perianal fistulizing Crohn\u2019s disease. Dis Colon Rectum. 2023:66:1359\u201372.","DOI":"10.1097\/DCR.0000000000002567"},{"key":"1524_CR104","doi-asserted-by":"publisher","first-page":"6132340","DOI":"10.1155\/2019\/6132340","volume":"2019","author":"MD Herreros","year":"2019","unstructured":"Herreros MD, Garcia-Olmo D, Guadalajara H, Georgiev-Hristov T, Brandariz L, Garcia-Arranz M. Stem cell therapy: a compassionate use program in perianal fistula. Stem Cells Int. 2019;2019:6132340.","journal-title":"Stem Cells Int"},{"key":"1524_CR105","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","volume":"388","author":"J Pan\u00e9s","year":"2016","unstructured":"Pan\u00e9s J, Garc\u00eda-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281\u201390.","journal-title":"Lancet"},{"key":"1524_CR106","doi-asserted-by":"crossref","unstructured":"Garcia-Olmo D, Gilaberte I, Binek M, et al. Follow-up study to evaluate the long-term safety and efficacy of Darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing Crohn\u2019s disease: ADMIRE-CD Phase 3 Randomized Controlled Trial. Dis Colon Rectum. 2022;65:713\u201320.","DOI":"10.1097\/DCR.0000000000002325"},{"key":"1524_CR107","doi-asserted-by":"crossref","unstructured":"Dietz AB, Dozois EJ, Fletcher JG, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn\u2019s disease. Gastroenterology. 2017;153:59\u201362.e2.","DOI":"10.1053\/j.gastro.2017.04.001"},{"key":"1524_CR108","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/ecco-jcc\/jjac192","volume":"17","author":"C Reenaers","year":"2023","unstructured":"Reenaers C, Gillard RP, Coimbra C, et al. Clinical and MRI Evolution after local injection of bone marrow-derived mesenchymal stem cells in perianal fistulae in Crohn\u2019s disease: results from a prospective monocentric study. J Crohns Colitis. 2023;17:728\u201337.","journal-title":"J Crohns Colitis"},{"key":"1524_CR109","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1053\/j.gastro.2022.08.051","volume":"163","author":"M Balasubramaniam","year":"2022","unstructured":"Balasubramaniam M, Nandi N, Aswani-Omprakash T, Sebastian S, Sharma V, Deepak P. Identifying care challenges as opportunities for research and education in inflammatory bowel disease in South Asia. Gastroenterology. 2022;163:1145\u201350.","journal-title":"Gastroenterology"},{"key":"1524_CR110","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s12664-023-01399-9","volume":"42","author":"A Singh","year":"2023","unstructured":"Singh A, Kakkar C, Garg S, et al. Clinical and magnetic resonance imaging spectrum of complex perianal fistulizing Crohn\u2019s disease: A cohort study from northern India. Indian J Gastroenterol. 2023;42:668\u201376.","journal-title":"Indian J Gastroenterol"},{"key":"1524_CR111","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Park S, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1133\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1524_CR112","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/DCR.0000000000001606","volume":"63","author":"RB Rajaram","year":"2020","unstructured":"Rajaram RB, Hilmi IN, Roslani AC. Low acceptance of surgery results in high morbidity and mortality among Asian patients with IBD. Dis Colon Rectum. 2020;63:415\u20137.","journal-title":"Dis Colon Rectum"},{"key":"1524_CR113","doi-asserted-by":"publisher","unstructured":"Aswani-Omprakash T, Balasubramaniam M, McGarva J, et al. Post-traumatic stress disorder symptoms are frequent among inflammatory bowel disease patients of South Asian descent-A case-control study. Indian J Gastroenterol. 2023. https:\/\/doi.org\/10.1007\/s12664-023-01424-x.","DOI":"10.1007\/s12664-023-01424-x"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-024-01524-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-024-01524-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-024-01524-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:04:54Z","timestamp":1709942694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-024-01524-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1524"],"URL":"https:\/\/doi.org\/10.1007\/s12664-024-01524-2","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"20 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jalpa Devi: no relevant conflicts of interest exist. David H. Ballard: research support from an Investigator-Initiated Study from Takeda Pharmaceuticals. Tina-Aswani Omprakash: no relevant conflicts of interest exist. Alyssa M. Parian: no relevant conflicts of interest exist. Parakkal Deepak: consultant or on an advisory board for Janssen, Pfizer, Prometheus Biosciences, Boehringer Ingelheim, AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, CorEvitas LLC and Scipher Medicine Corporation. He has also received funding under a sponsored research agreement unrelated to the data in the paper from Takeda Pharmaceutical, Arena Pharmaceuticals, Bristol Myers Squibb-Celgene and Boehringer Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology or the printer\/publishers are responsible for the results\/findings and content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}